Nuclear Fuel Cycle & Isotopes
From uranium ore to spent fuel to medical isotopes: the conversion / enrichment / HALEU / fuel / reprocessing / decommissioning / isotope chokepoints the nuclear revival cannot route around
Nuclear power is back in favor on AI data-center electricity demand, energy security, and the push to de-Russify supply. Yet the real bottleneck to getting a reactor running usually sits past the mine, in every processing step after it. The chain's hardest chokepoints are highly concentrated: (1) uranium conversion (U3O8 to UF6) runs through only about four plants worldwide (Orano / Rosatom / Cameco / US Solstice); (2) enrichment is roughly 40% Rosatom alone and over 60% combined with CNNC; (3) HALEU, the high-assay fuel that advanced and micro reactors need, had near-zero Western capacity and long depended on Russia, with Centrus the only domesticated Western source. Midstream sits fuel-assembly manufacturing (Westinghouse / Framatome / GNF), tied one-to-one to reactor type and extremely sticky on the customer side. Downstream lies the back end the West has barely built: spent-fuel reprocessing, plus steadily growing decommissioning and waste disposal. The chain ends at the hottest and least-consensus segment today, medical and industrial isotopes (a radiopharmaceutical theranostics boom). Value pools in the links where supply is hardest to expand: HALEU, conversion, enrichment, and the licensed back end. Pure-play investable names are scarce, and much of the positioning is held by state enterprises (Orano / Rosatom / CNNC) and private leaders (Holtec / Curium). Reactor operators and utilities sit in the sister topic 'Energy / Power Supply Chain.' This page lays out 9 layers upstream to downstream, a qualitative map of positioning and value capture only, with no return forecasts (YMYL).
Uranium Resources & Physical Uranium
The start of the fuel cycle: mining uranium and processing it into uranium concentrate (U3O8 / yellowcake). Supply is highly concentrated, with Kazakhstan alone supplying roughly 40% of global primary uranium output. Layer on de-Russification / de-Kazakhification supply-security demands and an up-cycle in uranium prices, and the mine-side narrative is strong, though at bottom this is a commodity cycle and miners have essentially no pricing power over uranium. WARNING: the detailed roster of major uranium miners (NexGen / Energy Fuels / CGN Mining and others) is already covered in depth in the nuclear-fuel layer of the sister topic 'Energy / Power Supply Chain.' This layer keeps only the leading-name skeleton with a source note, and puts the incremental value into two pieces the energy topic lacks: (1) physical-uranium vehicles (SPUT / Yellow Cake / uranium ETFs), financial instruments that hold yellowcake or a basket of the uranium chain directly rather than touching mining equities; (2) a set of second-tier producers restarting or under construction that form new de-Russified supply. By share of value, the mine is the chain's largest in volume yet the weakest-moat link, with gross margins at the mercy of the uranium price.
Largest Western uranium miner, and holder of 49% of Westinghouse, spanning mining, conversion, fuel, and reactor licensing (conversion positioning detailed in Layer 2).
World's largest uranium miner, low-cost ISR production, running global supply on a 'value over volume' strategy; the London GDR is investable but the company is state-controlled.
World's largest physical-uranium vehicle: raises capital to buy yellowcake in the spot market and warehouse it long term, no mining and no processing, just stockpiling uranium.
Jersey-registered physical-uranium investment company, with a framework offtake agreement with Kazatomprom under which it exercises annually to buy and hold U3O8.
Operator of the producing Langer Heinrich uranium mine in Namibia, and owner of Canada's PLS development project via its acquisition of Fission.
Producer at Australia's Honeymoon ISR uranium mine, and holder of 30% of Alta Mesa in the US (operated by enCore).
Pure-play uranium producer with two Wyoming ISR projects, Lost Creek and Shirley Basin, in production and ramping, focused on domestic US supply.
US domestic ISR uranium producer (Rosita / Alta Mesa central processing plant in Texas), running Alta Mesa as a 70/30 joint venture with Boss Energy.
Developer of the large Tumas sandstone uranium project in Namibia (pre-FID), aiming to grow into a first-tier low-cost producer.
Developer of the high-grade Dasa uranium project in Niger (under construction), with several uranium offtake letters of intent signed.
Pure uranium-theme ETF focused on global uranium miners plus physical uranium (holdings include SPUT).
Broad uranium-theme ETF covering miners plus nuclear-fuel-component companies (tracks the Solactive Global Uranium & Nuclear Components Index).
Uranium Conversion (U3O8 → UF6)
The most overlooked yet genuinely choking layer of the fuel chain: converting uranium concentrate into uranium hexafluoride (UF6) so it can feed centrifuges for enrichment. The plants that can do commercial conversion can be counted on one hand. The Western merchant market is essentially a four-firm oligopoly: Orano (France), Rosatom (Russia), Cameco (Canada), and US Solstice / ConverDyn (China's CNNC has separate ten-thousand-tonne capacity but mostly self-supplies and does not enter the international merchant market, so it falls outside this measure). By merchant capacity and output (early 2024), shares run roughly Orano ~28.7%, Rosatom ~26.5%, Cameco ~18.9%, US ~18.3%, over 90% combined across the four. Supply is extremely rigid (building or restarting a conversion plant runs in years), and de-Russification squeezes Russian capacity out of Western procurement, so conversion fees (the UF6 price) at one point ran up harder than uranium itself and approached record highs. The energy topic covers this with a single card; this layer is the chokepoint laid out in full. Key change: US conversion assets folded into the listed company Solstice in 2025 via the Honeywell spin-off, turning 'the only US converter' from private into directly investable.
World's largest uranium converter: two-stage line of Malvési (U3O8 to UF4) in France plus Comurhex II (UF4 to UF6) at Tricastin, at full output more than a quarter of global UF6 capacity.
Holder of Russian conversion capacity (Seversk and others), selling externally through its subsidiary TENEX, the world's second-largest conversion source.
Operator of Canada's only commercial conversion plant, Port Hope (Ontario), the only one of the four Western converters that is a listed pure play with its own mine supply.
Operator of the only US commercial conversion plant, Metropolis Works (Illinois), marketing its UF6 through ConverDyn, its joint venture with General Atomics, the only commercial source of domestic US UF6.
Holder of China's uranium conversion capacity, with a roughly 10,000-tonne uranium purification and conversion center built (Lanzhou and elsewhere), mainly self-supplying China's nuclear fleet and largely outside the international market.
US ISR uranium miner building a new US conversion plant through its subsidiary UR&C (NRC docketing granted March 2026), targeting a vertically integrated mine-to-conversion model.
Uranium Enrichment (SWU)
One of the fuel chain's hardest chokepoints: enriching converted UF6 to the U-235 assay reactors need, low-enriched uranium (LEU, <5%), measured in separative work units (SWU). This is an oligopoly-plus-state-capital, high-barrier business; the moat is gas-centrifuge / laser technology, regulatory licensing, and decades of know-how. Capacity is highly concentrated: Russia's Rosatom alone is about 40%, Urenco about 27%, CNNC expanding fast (about 63% combined with Russia in 2024), and France's Orano about 12%, which is the sharpest 'Russia dependence' Western utilities face. The US Prohibiting Russian Uranium Imports Act of 2024 (signed 2024-05-13, effective 2024-08-11, waivers terminating no later than 2028-01-01), together with DOE's HALEU enrichment contract (ceiling about $2.7 billion) and a separate LEU procurement task order, is driving Urenco / Orano / Centrus to expand capacity together. Pure-play enrichment names you can buy directly are extremely scarce, essentially only Centrus and laser-route Silex. WARNING: this layer deepens the enrichers the energy topic already covers lightly, filling in the SWU share structure, the Russian capacity share, the ban timeline, and expansion commitments.
World's largest uranium enricher, capacity totaling over 27 million SWU/year, the center of the 'Russia dependence' story.
Largest Western commercial uranium enricher (gas centrifuge), spanning the UK, Germany, and the Netherlands plus the new Eunice plant in New Mexico, US.
Only US-listed pure-play enricher, the Piketon American Centrifuge plant in Ohio, rebuilding US-scale enrichment and HALEU capability on domestic technology.
Integrated French nuclear-fuel major, Tricastin / Georges Besse II centrifuge enrichment plant, the West's second-largest enrichment capacity.
China's national enrichment provider, indigenous centrifuge technology, executing the state policy of 'enrichment self-sufficiency', third-largest capacity globally and the fastest-growing.
Laser-enrichment (SILEX) technology developer, commercializing the laser route through GLE (Silex 51% / Cameco 49%), the only new enrichment route being advanced outside centrifuges.
HALEU & Advanced Fuel Feedstock
HALEU (high-assay low-enriched uranium, 5%-20%) is the sharpest bottleneck of the advanced-reactor wave. A key distinction: not every SMR needs HALEU. The two mainstream light-water SMRs (NuScale VOYGR, GE Hitachi BWRX-300) still use standard LEU (<5%) at the same grade as today's large reactors. The designs that truly depend on HALEU are advanced non-light-water reactors (the sodium-cooled fast reactor Natrium, the high-temperature gas reactor Xe-100) and various microreactors (Oklo), with about 9 in 10 of the designs funded by DOE's advanced reactor demonstration program relying on HALEU. The crux: before 2022 the only commercial HALEU source was Russia's TENEX, Western domestic commercial HALEU capacity was near zero, and domestication is the real bottleneck. Through the HALEU Availability Program (enrichment contracts totaling a ceiling of about $2.7 billion) plus offtake mechanisms, DOE is backing four firms, Centrus, Urenco USA, Orano USA, and startup General Matter (plus laser-route GLE), to stand up HALEU capacity from zero; a separate LEU (<5%) procurement task order runs in parallel to expand domestic standard low-enriched capacity, and the two are reported separately and must not be conflated. Centrus is the purest 'bottleneck positioning' name in the whole segment; the demand-side anchor is in Layer 6.
Only company NRC-licensed to commercially produce HALEU on domestic centrifuge technology in the US (Piketon, Ohio), the de facto sole source for Western HALEU domestication.
The overall anchor for US HALEU domestication: standing up multiple firms' capacity from zero via about $2.7 billion in HALEU enrichment contracts plus offtake / competitive mechanisms (the LEU procurement task order is issued separately and reported apart).
Laying HALEU front-end capacity at the US Eunice plant: NRC-approved to enrich to 10%, expanding LEU to feed HALEU.
Isotope-enrichment company entering HALEU and Li-6 advanced fuel feedstock through its subsidiary Quantum Leap Energy (QLE) using a laser 'quantum enrichment' method.
Nuclear Fuel Manufacturing / Fuel Assemblies
Turning upstream-enriched UF6 into UO2 pellets, sintering and loading them into tubes as fuel rods, then bundling them into assemblies delivered to reactors: the link with the deepest technical barriers and the tightest reactor-type lock-in in the fuel cycle (assemblies must be certified one-to-one to a specific reactor type), and a core increment the energy topic does not cover at all. Global commercial PWR / BWR fuel is highly oligopolized among Westinghouse, Framatome, Global Nuclear Fuel (GNF), Mitsubishi, Korea's KEPCO, Russia's TVEL, and CNNC, with very high customer stickiness and high switching costs. This layer also takes in next-generation fuels for advanced reactors: accident-tolerant fuel (ATF), metallic fuel, and the TRISO coated-particle fuel that high-temperature gas reactors and microreactors need, the last produced at scale under license by BWXT in the US, with X-energy building its own TRISO-X line. Most names are the nuclear-fuel divisions of large groups or state enterprises; investable listed pure fuel-manufacturing names are scarce, and value capture often runs through indirect exposure via the parent. HALEU feedstock supply is in Layer 4.
One of the core firms with US production-grade TRISO fuel capability, plus naval-reactor fuel and nuclear-grade manufacturing, a chokepoint node in the advanced-fuel chain.
World's largest PWR fuel manufacturer plus reactor licensor (AP1000 / AP300), with fuel and reactor type doubly locked.
Supplies global BWR fuel through the joint venture it leads, Global Nuclear Fuel (launched the next-generation GNF4 in 2025), and drives BWRX-300 SMR fuel demand.
French nuclear-fuel and reactor major, supplies PWR fuel assemblies plus ATF R&D.
Building its own TRISO-X fuel line to supply TRISO to its Xe-100 high-temperature gas reactor and third parties, vertically integrating fuel plus reactor.
Supplies Japan's PWR fuel through its subsidiary Mitsubishi Nuclear Fuel; nearly all of Japan's PWRs are turnkey-supplied by MHI.
Supplies all of Korea's nuclear fuel through its subsidiary KEPCO Nuclear Fuel, tied to Korea's nuclear fleet and exports (APR1400).
Metallic-fuel technology developer, targeting refueling of the in-service light-water / CANDU fleet to lift power output and safety margin.
Russia's fuel-manufacturing monopoly, long the world's only commercial source of HALEU at scale, with VVER fuel tied to a large in-operation fleet.
Integrated Chinese nuclear-fuel-cycle state enterprise, its in-house fuel manufacturing covering the country's vast fleet under construction.
Advanced Reactors & SMRs (Fuel / HALEU Demand-Side Anchor)
This layer is the demand-side anchor of the fuel chain, answering one question only: who is pulling demand for nuclear fuel (HALEU and TRISO in particular). Reactor operators, utilities, and the reactors themselves are detailed in the energy topic and not repeated here; this layer names only the 'developers pulling fuel demand' and is deliberately trimmed to avoid overlap. The key split runs across two demand types: (1) advanced non-light-water reactors needing HALEU (5%-20%), the sodium-cooled fast reactors / microreactors, high-temperature gas reactors, and fluoride-salt-cooled reactors, the main driver of incremental HALEU / TRISO demand, where Western HALEU capacity is still ramping and the supply-demand gap is itself the opportunity for the up- and midstream (Centrus / BWXT); (2) light-water SMRs using standard LEU (<5%), whose fuel supply runs on the mature commercial chain and adds no HALEU increment. Note: vertically integrated X-energy (Xe-100, self-supplying TRISO-X) and GE Vernova (BWRX-300, fed by its own GNF) already have cards in Layer 5 and are not double-weighted here. Each entry stresses its pull direction on the fuel chain rather than reactor economics.
Sodium-cooled microreactor (Aurora) needing HALEU plus an in-house spent-fuel recycling plant, pulling both HALEU demand and back-end recycling (recycling positioning detailed in Layer 7).
The Natrium sodium-cooled fast reactor needs large amounts of HALEU, the landmark private anchor on the HALEU demand side.
Fluoride-salt-cooled high-temperature reactor (KP-FHR) using TRISO fuel plus Flibe molten salt, pulling TRISO and HALEU demand.
Portable microreactors (ZEUS / ODIN / KRONOS) needing HALEU, plus an in-house HALEU fuel transport / logistics platform.
Light-water SMR (VOYGR) using standard LEU rather than HALEU, pulling the mature commercial fuel chain rather than a HALEU increment.
Light-water SMR (470MWe three-loop PWR) using UO2-LEU, pulling the mature PWR fuel chain.
SMR-300 light-water reactor using LEU, pulling the mature PWR fuel chain; also deep in spent-fuel dry storage / decommissioning (see Layers 7 and 8).
Spent-Fuel Management · Reprocessing & Recycling
Where a reactor's discharged spent fuel goes decides whether the whole fuel cycle is 'open' (store then dispose directly) or 'closed' (reprocess to recover plutonium / uranium and remake MOX). Commercial reprocessing is heavily nationalized: France's Orano runs La Hague, which alone holds about half of global light-water-reactor spent-fuel reprocessing capacity, while Russia's Rosatom, China's CNNC, and Japan's JNFL (the Rokkasho plant is still in final commissioning after repeated delays) are controlled by states or utilities. The US has indefinitely shelved civilian reprocessing since 1977 and has done no commercial reprocessing since, a structural chokepoint. At the same time global spent fuel has no final home and keeps piling up away from reactors (the US alone holds roughly 86,000-90,000 tonnes across 70-plus sites and rising), driving rigid demand for dry-storage casks and consolidated interim storage, where the segment leader Holtec is private. Advanced closed-cycle startups (Oklo / Curio / SHINE / Lightbridge and others) are heating up on early-2026 DOE funding (in February 2026 about $19 million in recycling R&D was awarded to five firms: Oklo / Curio / SHINE / Flibe / Alpha Nur) and an executive order, but most sit at the experimental or pilot stage and are unlisted. Net effect: investable listed pure plays are scarce, and value pools more in state enterprises and private leaders.
Operator of France's La Hague, the world's largest commercial reprocessing plant, holding about half of global light-water-reactor spent-fuel reprocessing capacity; also runs MOX manufacturing and interim storage (Orano TN).
Leader in dry-storage casks (HI-STORM / HI-STAR) with top market share; advancing the HI-STORE consolidated interim storage facility (CISF) in New Mexico; holds and decommissions shut-down reactors through HDI.
Does commercial spent-fuel reprocessing through Mayak (RT-1), advancing the full-scale RT-2 reprocessing plant and a MOX / REMIX closed cycle.
Building a 200-tonne/year commercial demonstration reprocessing plant at Jinta in Gansu plus a second line of the same capacity, advancing China's closed fuel cycle.
Supplies spent-fuel storage / transport casks (MAGNASTOR and others) and interim-storage solutions through its wholly owned subsidiary NAC International, an investable proxy for back-end spent-fuel equipment.
Joint venture of Orano USA and Waste Control Specialists, NRC-licensed to build a consolidated interim storage facility (CISF) at Andrews in West Texas, scalable in phases to 40,000 tonnes of spent fuel.
Developing its proprietary NuCycle proliferation-resistant integrated spent-fuel recycling process, targeting a pilot module in 2027; one recipient of DOE's February 2026 SNF recycling funding.
European lead-cooled fast reactor plus MOX closed-fuel-cycle developer, proposing to close the cycle by 'using spent fuel / depleted uranium as fuel'.
Deep-borehole spent-fuel / high-level-waste disposal solution provider, advancing a universal canister system and field validation.
Decommissioning & Nuclear Waste Disposal
Dismantling and decontaminating units after shutdown plus treating, transporting, and disposing of radioactive waste is the fuel cycle's 'final chapter.' The drivers are a globally aging fleet and early closures in some countries, so the decommissioning services market grows structurally over time, with over 199 units entering decommissioning by 2050. Investable listed names are relatively plentiful here: US DOE environmental cleanup is the largest single buyer, and giant contracts like Hanford and Savannah River (a single award can reach tens of billions of dollars, mostly taken on through JV consortia) are split among listed engineering firms such as Amentum, Fluor, BWXT, and AECOM; the radioactive-waste treatment / disposal side has listed names like Perma-Fix, Veolia, and Sweden's Studsvik, but low-level-waste disposal sites are held by private EnergySolutions, making them scarce. Final geologic repositories (Finland's Onkalo, Sweden's SKB, France's Andra) are state entities, included only as background. Overall: engineering contractors earn long-cycle cost-plus and milestone fees, and a disposal-site license is the scarce moat. WARNING: Westinghouse (held by Cameco) also does unit decommissioning / dismantling; for the exposure, see Cameco in Layers 1 and 5.
Listed engineering contractor formed in 2024 from the spin-off and merger of Jacobs' Critical Mission Solutions business, a main holder of US DOE nuclear cleanup / Hanford and similar large environmental-management contracts.
Global engineering major, taking on DOE environmental cleanup through JVs: Hanford tank disposal (H2C), Central Plateau cleanup, Savannah River operations.
Nuclear-component / naval-nuclear manufacturer, leading the Hanford tank disposal contract on the environmental-services side (H2C, a BWXT + Amentum + Fluor JV, about $45 billion ceiling over 10 years).
Leader across US low-level-waste disposal (the Clive site in Utah), radioactive-material transport / treatment / recycling, and decommissioning; nearly every US nuclear plant and DOE uses its services.
Engineering-consulting major, leading the Hanford Central Plateau Cleanup and other DOE environmental projects.
Operates several nuclear-waste treatment facilities, handling radioactive and mixed waste for DOE / DoD / commercial nuclear and hospitals / research, a small-cap pure radioactive-waste treatment name.
Does nuclear-facility decontamination and decommissioning plus low- and intermediate-level waste treatment through Veolia Nuclear Solutions (which integrated Kurion and others), covering the US / France / UK / Japan / Canada.
Swedish nuclear services / software firm: fuel and materials inspection, fuel and core management software (Scandpower), and decommissioning and radioactive-waste treatment solutions.
Engineering-consulting major; after spinning its Critical Mission Solutions / nuclear-government services into Amentum in 2024, retains a minority Amentum stake plus some commercial nuclear / engineering-consulting business.
US nuclear-unit decommissioning / dismantling contractor (led the Vermont Yankee decommissioning), private.
Private engineering major, historically involved in DOE nuclear-waste disposal megaprojects such as Hanford vitrification (WTP).
State entities for final geologic repositories: Finland's Posiva (Onkalo, the world's first), Sweden's SKB (the world's second), and France's Andra (Cigéo).
Medical & Industrial Isotopes
This layer is the far downstream of the fuel cycle's 'isotope' end, taking radionuclides produced by reactors / accelerators through production, purification, radiopharmaceutical formulation, and radiopharmacy distribution, finally into imaging and oncology treatment. By use it splits into four sub-groups: (1) diagnostic isotopes Mo-99 / Tc-99m (the workhorse of nuclear-medicine imaging, short half-life, distributed close to use via generators); (2) therapeutic / theranostic isotopes Lu-177 / Ac-225 / Ra-223 (theranostic radiopharmaceuticals, the hottest and least-consensus end today, lifted by the ramp of Novartis's Pluvicto / Lutathera and an M&A wave among big pharma in 2023-24); (3) industrial isotope Co-60 (sterilization / irradiation / radiography, steady essential demand); (4) stable-isotope enrichment feedstock (Yb-176 to Lu-177, Mo-100 to Mo-99, the upstream raw materials for radiopharmaceuticals). The core tension is a supply bottleneck: Ac-225 and Lu-177 capacity is constrained by reactors / accelerators and radiochemistry infrastructure, with demand running far ahead of supply. The difficulty is that most pure producers are private (Curium / NorthStar / SHINE), investable listed pure plays are scarce, and you have to use Lantheus, Telix, Eckert & Ziegler, Cardinal, BWXT (medical division), and ASPI as proxies; you also have to separate 'the ones producing isotopes' from 'the demand side making drugs with isotopes.'
Both isotope producer and drugmaker: one of the world's largest nuclear-medicine companies, a supply hub for Mo-99 / Tc-99m generators and PET / SPECT imaging agents, and building its own Lu-177 and other therapeutic radiopharmaceutical pipeline.
Mainly a drugmaker using isotopes, with some production: US leader in PSMA PET imaging agents (PYLARIFY), and entering theranostic therapeutic radiopharmaceuticals and radioligand-therapy capacity via acquisition.
Demand side plus in-house production: the benchmark drugmaker in theranostic radiopharmaceuticals (Pluvicto / Lutathera, Lu-177), building global radioligand-therapy capacity to secure supply.
Distribution hub plus added production: runs the largest radiopharmacy network in the US for radiopharmaceutical distribution, and building its own Ac-225 capacity (Indianapolis theranostics advancement center).
Demand side making drugs with isotopes: a pure-play theranostic radiopharmaceutical company, with imaging and treatment pipelines for prostate cancer / kidney cancer / brain tumors.
Isotope producer plus radiopharmaceutical components: a producer of radionuclides and sealed / unsealed sources, supplying radiopharmaceutical isotopes, radiochemistry feedstock, and medical / industrial radiation sources.
Demand side making drugs with isotopes: a targeted-alpha-therapy radiopharmaceutical company, Xofigo (Ra-223) plus an Ac-225 PSMA pipeline in development.
Produces / supplies industrial isotopes: supplies Co-60 through its Nordion division, used for medical-device / pharma sterilization, irradiation, and cancer-radiotherapy sources.
Produces stable-isotope enrichment feedstock: an upstream enriched-feedstock supplier for radiopharmaceuticals (Yb-176 to Lu-177, Mo-100 to Mo-99), on the feedstock side rather than the drug side.
Isotope producer: has exited Mo-99 and now focuses on non-reactor production of therapeutic isotopes such as Ac-225 and Cu-67.
Isotope producer: has produced Lu-177 and other therapeutic isotopes via a fusion neutron source, with a planned Mo-99 line, also in industrial radiography, and developing spent-fuel recycling (see Layer 7).
Demand-side M&A signal: a pure radiopharmaceutical company bought out in the 2023-24 theranostics M&A wave, showing big pharma's scramble for therapeutic-isotope pipelines.
Isotope producer (background): a national-level entity supplying global Mo-99 / Tc-99m from research reactors, forming the base supply layer for diagnostic isotopes.